logo
logo
AI + EXCLUSIVE DATA

AI analyzes funding data you can't access anywhere else

Our proprietary AI monitors 15,000+ companies and identifies which funded companies need YOUR specific solution right now.

10-25 personalized leads daily • 92% average intent score • Smart feed technology
Start with:
✓Flexible Plans • $39/mo or $29/mo annual
✓AI + real-time funding intelligence
✓Never see duplicates in your feed
INDUSTRY FIRST

Heartseed Raises $37 Million In Series C Funding To Accelerate Development Of Ipsc-Derived Stem Cell Therapy For Heart Failure

Jun 11, 2021•about 4 years ago

Amount Raised

$37 Million

Round Type

series c

Tokyo

Description

Heartseed, a Tokyo-based biotechnology company developing iPSC-derived cardiomyocytes for heart failure (HF), today announced it has raised 4 Billion-yen (approx. $37 Million) at Series C round, bringing its total financial backing to 8.2 Billion yen (approx. $75 Million) since its foundation in 2015.

Company Information

Company

Heartseed

Location

Tokyo, Tokyo, Japan

About

Heartseed will use the new funds to accelerate the initiation of global clinical trial of HS-001 for HF as well as to confirm its proof of concept in Phase 1/2 LAPiS study in Japan.

Company News

(3 articles)
Tue, 15 Sep 2020 07:00:00 GMT

Mutsuki Takano Was Appointed as CFO at Heartseed - Business Wire

Mon, 28 Jun 2021 07:00:00 GMT

Stem cell-based therapy for heart failure licensed in global collaboration - Longevity.Technology

Wed, 01 Nov 2023 07:00:00 GMT

Heartseed Succeeds in Stable Production of High Purity Cardiomyocytes Using iPS Cells from I Peace, A Major Step Forward in Advancing Autologous Cardiac Regenerative Medicine - Business Wire

FundzWatch™ Score

65
Medium Activity

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech